Table 2.
Drug Resistance Profiles and Subtypes of Longitudinal Single Genome Sequences
| Time postdiagnosis (weeks) | No. of sequences/total no. of sequences at time point (%) | Subtypea | RT resistance mutations |
|---|---|---|---|
| 34 | 24/25 (96%) | CRF19 | D67N, K101E, Y181C, G190A, T215L, K219E |
| 1/25 (4%) | CRF19 | D67N, K70R, K101E, Y181C, G190A, T215L, K219E | |
| 54 | 18/25 (72%) | CRF19 | D67N, K101E, Y181C, G190A, T215L, K219E |
| 1/25 (4%) | B | None | |
| 3/25 (12%) | CRF19/B | None | |
| 1/25 (4%) | CRF19/B/CRF19 | None | |
| 1/25 (4%) | B/CRF19 | D67N, K101E, Y181C, G190A, T215L, K219E | |
| 1/25 (4%) | CRF19/B | D67N, K101E | |
| 85 and 87b | 34/43 (79%) | CRF19/B | None |
| 2/43 (5%) | B | None | |
| 3/43 (7%) | B/CRF19/B | None | |
| 1/43 (2%) | CRF19/B/CRF19/B | None | |
| 1/43 (2%) | CRF19/B | D67N, K101E, Y181C, G190A | |
| 2/43 (5%) | CRF19 | D67N, K101E, Y181C, G190A, T215L, K219E | |
| 87 seminal plasma | 18/21 (86%) | B | None |
| 3/21 (14%) | CRF19/B | None |
a
HIV-1 subtypes were defined using SimPlot.
b
The results from blood plasma samples from weeks 85 and 87 postdiagnosis were combined, as the time points were less than 2 weeks apart.